Bristol-Myers Squibb Company is a global biopharmaceutical company incorporated in Delaware, engaged in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of innovative medicines for serious diseases including oncology, hematology, immunology, cardiovascular, and neuroscience. The company operates as a single reportable segment and competes with global research-based drug companies, smaller research firms, and generic manufacturers. BMS's common stock and multiple series of fixed-rate senior notes are listed on the New York Stock Exchange.

What is BMY's DredgeCap risk score?

DredgeCap's AI analysis rates BMY at 3.8/10 on the risk scale — Low risk. This score reflects dilution exposure, debt toxicity, liquidity position, and going-concern posture as disclosed in SEC filings.

Does BMY have a going concern warning?

No current auditor going-concern warning is flagged in BMY's SEC filings. Risk assessment is based on other filing-disclosed factors.

When did BMY last file with the SEC?

BMY's most recent SEC filing was a 10-K filed 2026-02-11. All filings are available on SEC EDGAR.

← BMY Overview

8-KMay 8, 2026

BMY — 8-K Filing

Track BMY for Alerts

8-K Items Disclosed

Item 5.07 — Submission of Matters to a Vote of Security Holders

Annual meeting / shareholder vote results.

BMY Filing Excerpt

CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2026 BRISTOL-MYERS SQUIBB COMPANY (Exact Name of Registrant as Specified in its Charter) Delaware 001-01136 22-0790350 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification Number) Route 206 & Province Line Road, Princeton, New Jersey 08543 (Address of Principal Executive Office) Registrant’s telephone number, including area code: (609) 252-4621 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title…

Current DredgeCap Risk Profile

Risk Score

3.8/10

MODERATE

Dilution

2.0

Debt Toxicity

4.5

Going Concern

✓ Not flagged

The risk profile above reflects the latest cached DredgeCap analysis for BMY. For the full filing-by-filing analyst report (red flags, primary risk driver, what moves the stock), open BMY's company page.

What is a 8-K?

A current report disclosing a material event that occurred between regular reporting periods. Companies are required to file an 8-K within four business days of certain events including earnings releases, executive changes, acquisitions, debt obligations, restructurings, and material agreements. Each 8-K specifies one or more 'Items' identifying which event triggered the filing.

More on BMY

The plain-language summary above is composed mechanically from the filing's reported numbers — no analysis or opinion. Form-type explainers and 8-K item descriptions are derived from SEC documentation. This page does not constitute investment advice. Always consult the original filing on SEC EDGAR for authoritative content, and consult a licensed financial advisor for investment decisions.